Positive Press Coverage Somewhat Unlikely to Impact Novartis (NVS) Share Price

News headlines about Novartis (NYSE:NVS) have trended positive on Wednesday, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Novartis earned a media sentiment score of 0.35 on Accern’s scale. Accern also gave news stories about the company an impact score of 49.4942377653097 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the news stories that may have impacted Accern’s rankings:

Novartis (NYSE:NVS) traded down $0.51 during mid-day trading on Wednesday, hitting $85.86. 796,682 shares of the company traded hands, compared to its average volume of 1,001,471. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 1.08. The firm has a market capitalization of $225,980.00, a PE ratio of 30.56, a P/E/G ratio of 2.55 and a beta of 0.74. Novartis has a twelve month low of $69.53 and a twelve month high of $86.90.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.25 by $0.04. The business had revenue of $12.41 billion during the quarter, compared to analysts’ expectations of $12.21 billion. Novartis had a net margin of 13.73% and a return on equity of 15.77%. The firm’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same period last year, the company posted $1.23 earnings per share. analysts predict that Novartis will post 4.77 EPS for the current fiscal year.

Several research analysts have commented on NVS shares. Zacks Investment Research upgraded shares of Novartis from a “hold” rating to a “buy” rating and set a $96.00 target price for the company in a report on Tuesday, September 19th. Leerink Swann raised their target price on shares of Novartis from $89.00 to $91.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a report on Tuesday, September 26th. Finally, Nord/LB reiterated a “neutral” rating on shares of Novartis in a report on Tuesday, January 2nd. Five equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the stock. Novartis currently has a consensus rating of “Hold” and a consensus price target of $85.32.

TRADEMARK VIOLATION NOTICE: This article was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.com-unik.info/2018/01/10/positive-press-coverage-somewhat-unlikely-to-impact-novartis-nvs-share-price.html.

About Novartis

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Insider Buying and Selling by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit